Circulating Tumor Cells (CTC) in Cancer

Recruiting

• Conditions: Cancer

• Registration Number: NCT04520672
• Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary

This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-08-05
• Study First Submitted QC: 2020-08-17
• Study First Posted: 2020-08-20
• Study Start: 2020-10-01
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-10
• Last Update Posted: 2025-03-12
• Primary Completion: 2030-08
• Study Completion: 2030-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

• Adult cancer patients
• All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included.
• All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma
• Written pathology report must be available.
• Written informed consent.

Exclusion Criteria

• No written informed consent.
• No proved diagnosis of malignancy by pathology report.
• Patients with the diagnosis of blood cancer

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival (OS) in heterogeneous cancer population	Screening (Visit 1) until the date of death (assessed up to 240 months)	overall survival (OS) in heterogeneous cancer population
Change in total number of isolated CTCs	Through study completion, an average of 20 years	Change in total number of isolated CTCs

Secondary Outcome Measures

Name	Time	Method
Progression free survival (PFS)	Through study completion, an average of 20 years	progression free survival (PFS) in the different cancer cohorts with different treatment regimes

Trial Locations

Locations (2)

University Hospital Basel; 🇨🇭 Basel, Switzerland

Department Oncology, Haematology & Immuntherapy, Kantonsspital Baselland; 🇨🇭 Liestal, Switzerland